Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Venglustat | C20H24FN3O2S | CID 60199242 - PubChem
Venglustat | 1629063-78-0
CNS inhibition of GCS by venglustat reduced glycosphingolipids in mouse ...
Venglustat for Fabry disease | Fabry Disease News
(PDF) Double-Edged Effects of Venglustat on Behavior and Pathology in ...
Venglustat worsens motor function and affects response to novelty of ...
PERIDOT – Patient ExpeRIence in fabry Disease On venglustaT | M.A.G.I.C ...
GCS inhibition by venglustat reduced glycosphingolipids and brain ...
Mean (+ standard deviation) venglustat plasma concentrations on Day 1 ...
Venglustat causes disparate effects on pathology in substantia nigra ...
Estudio sobre el efecto de venglustat en el dolor neuropático y ...
Successful Venglustat Phase 3 Trial Offers Hope for Gaucher
Sanofi's venglustat results: Gaucher win, mixed Fabry outcome | Layla ...
Venglustat (GZ402671) for Fabry Disease Clinical Trial 2022 | Power
Sanofi’s venglustat succeeds in Phase 3 Gaucher trial but fails ...
Studie zur Bewertung der Wirkung von Venglustat im Vergleich zur ...
Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial ...
Sanofi Reports Divergent Phase III Venglustat Results in Gaucher & Fabry
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in ...
venglustat
Phase 3 Study of Venglustat Meets Key Endpoints for Type 3 GD
venglustat (GZ402671) / Sanofi
Venglustat inhibits protein N-terminal methyltransferases 1 in a ...
Double‐Edged Effects of Venglustat on Behavior and Pathology in Mice ...
Venglustat for treating late onset GM2 gangliosidosis, GM1 ...
Structure-Activity Relationship Studies of Venglustat on NTMT1 ...
Venglustat Analogues with Enhanced Inhibition for Protein N-Terminal ...
Venglustat combined with imiglucerase for neurological disease in ...
Structure–Activity Relationship Studies of Venglustat on NTMT1 ...
MOVES-PD Clinical Trial Results - Venglustat - Cure Parkinson's
Venglustat Inhibits Protein N-Terminal Methyltransferase 1 in a ...
Phase III breakthrough for venglustat in type 3 Gaucher disease ...
Safety and efficacy of venglustat in GBA1-associated Parkinson's ...
(PDF) Venglustat combined with imiglucerase for neurological disease in ...
venglustat | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Estudio sobre Venglustat e Imiglucerase en Adultos con Enfermedad de ...
Press Release: Sanofi’s venglustat met all primary endpoints in a phase ...
Mixed data mars Sanofi's venglustat programme | pharmaphorum
Enhanced Brain Connectivity Observed With Venglustat Plus Imiglucerase ...
FDA PreCheck Launches, Sanofi Venglustat Results
Sanofi’s Venglustat Clears Phase 3 in Neurological Gaucher Disease
Data show oral venglustat beats ERT for neurological symptoms
Venglustat for Gaucher Disease Clinical Trial 2023 | Power
Safety and Efficacy of Venglustat Assessed in GBA Gene Carriers With ...
Venglustat Malate | C24H30FN3O7S | CID 60199241 - PubChem
(A) Structure of venglustat, [(3S)-1-azabicyclo[2.2.2]octan-3-yl ...
Journal of Medicinal Chemistry | Vol 65, No 18
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at ...
Pipeline
Venglustat, an orally administered glucosylceramide synthase inhibitor ...
Frontiers | Fabry disease: Mechanism and therapeutics strategies
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral ...
Historical Control Analysis Demonstrates Greater Long‐Term Reduction in ...
Fabry Disease | M.A.G.I.C Clinic
Treatment of Fabry Disease: Established and Emerging Therapies
JCI - Accumulation of α-synuclein mediates podocyte injury in Fabry ...
(PDF) Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in ...
25亿美元收购抗癌新锐之后，赛诺菲新任CEO公布未来研发版图_凤凰网
ic Disease | MedChemExpress (MCE) Life Science Reagents
筋強直性ジストロフィー1型、重症化の新たな仕組みを発見 - 遺伝性疾患プラス
Figure 1 from Development of Lanzyme as the Potential Enzyme ...
Ibiglustat (Venglustat) | Glucosylceramide Synthase Inhibitor ...
潜在"first-in-class"疗法！赛诺菲戈谢病新药在中国获批临床 研究开发 | 华源医药网
Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic ...
赛诺菲venglustat帕金森病失利，还有哪些挫折？|帕金森病|鞘糖脂类|赛诺菲|挫折|失利|-健康界
2021年6月 | 失败临床研究TOP10 基于医药魔方网站行业快讯板块、NextPharma数据库以及公开信息，2021年6月的《临床研究 ...
Targeting Glycosphingolipid Metabolism in ADPKD: Another Roadblock for ...
(PDF) SAT-112 CLINICAL TRIAL OF VENGLUSTAT, A GLUCOSYLCERAMIDE SYNTHASE ...
Science
Highlights from the May 2023 Issue – AJKD Blog
(PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ...
%20for%20Fabry%20Disease.png?md=1)
